Marine natural products and their synthetic derivatives for cancer therapy

Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs

Volumn , Issue , 2010, Pages 613-643

  Jiang, Tao ^a   Zhang, Puyong ^a   Chen, Shaopeng ^a   Li, Guoqiang ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885748506     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0020-3_24     Document Type: Chapter

References (143)

1. Tan LT. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry (Elsevier). 2007;68(7):954-79. (Pubitemid 46413338)
2. Banerjee S, Wang ZW, Mohammad M, Sarkar F.H., et al Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod. 2008;71:492-6. (Pubitemid 351549382)
3. Dembitsky VM, Gloriozova TA, Vladimir VP Novel antitumor agents: marine sponge alkaloids, their synthetic analogues and derivatives. Mini Rev Med Chem. 2005;5:319-36. (Pubitemid 40331048)
4. Mayer AMS, Gustafson KR Marine pharmacology in 2001-2: antitumour and cytotoxic compounds. Eur J Cancer 2004;40:2676-704. (Pubitemid 39574721)
5. Mayer AMS, Gustafson KR Marine pharmacology in 2003-2004: anti-tumour and cytotoxic compounds. Eur J Cancer 2006;42:2241-70. (Pubitemid 44307627)
6. Kobayashi J, Murayama T, Ishibashi M., Kosuge S, et al New indole alkaloids from the Okinawan marine sponge Hyrtios erecta. Tetrahedron 1990;46(23):7699-702. (Pubitemid 20383630)
7. Helbecque N, Moquin C, Bernier J.L., Morel E., et al Grossularine-1 and grossularine-2, carbolines from Dendrodoa grossularia as possible interca-lative agents. Cancer Biochem Biophys. 1987;9(3):271-9.
8. Moquin-Pattey C., Guyot M. Cytotoxic α-carbolines from the tunicate: Dendrodoa grossularia. Tetrahedron 1989; 45 (11):3445-50.
9. Gul W, Hamann MT Indole alkaloid marine natural products: an established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. Life Sci. 2005;78:442-53. (Pubitemid 41653494)
10. Deveau AM, Labroli MA, Dieckhaus C.M., Barthen MT, et al The synthesis of amino-acid functionalized beta-carbolines as topoisomerase II inhibitors. Bioorg Med Chem Lett. 2001;11:1251-5. (Pubitemid 32434345)
11. Funayama Y, Nishio K, Wakabayashi K., Nagao M, et al Effects of beta-and gamma-carboline derivatives of DNA topoisomerase activities. Mutat Res. 1996;349:183-91.
12. Song Y, Wang J, Teng S., Kesuma D, et al Beta-carbolines as specific inhibitors of cyclin-dependent kinases. Bioorg Med Chem Lett. 2002;12:1129-32. (Pubitemid 34242818)
13. Song Y, Kesuma D, Wang J., Deng Y, et al Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. Biochem Biophys Res Commun. 2004;317:128-32. (Pubitemid 38401973)
14. Castro AC, Dang LC, Soucy F, Grenier L., et al Novel IKK inhibitors: β-carbolines. Bioorg Med Chem Lett. 2003;13:2419-22.
15. Beljanski M, Beljanski MS Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp Cell Biol. 1982;50:79-87. (Pubitemid 12185281)
16. Xiao S, Lin W, Wang C., Yang M. Synthesis and biological evaluation of DNA targeting flexible side-chain substituted β-carboline derivatives. Bioorg Med Chem Lett. 2001;11:437-41. (Pubitemid 32165203)
17. Davidson BS. Ascidians: producers of amino acid-derived metabolites. Chem Rev. 1993;93:1771-91.
18. Rinehart KL J.r., Kobayashi J, Harbour G.C., Gilmore J., et al Eudistomins A-Q, β-carbolines from the antiviral Caribbean tunicate Eudistoma oliva-ceum. J Am Chem Soc. 1987;109:3378-87.
19. Tsuda M, Kobayashi J. Structures and biogenesis of manzamines and related alkaloids. Heterocycles 1997;46:765-94. (Pubitemid 127740650)
20. (a) Jimenez C, Quinoa E, Adamczeski M, Hunter LM, et al. Novel sponge-derived amino acids 12: tryptophan-derived pigments and accompanying sesterterpenes from Fascaplysinopsis reticulata. J Org Chem. 1991;56:3403-10.
21. (b) Bourguet-Kondracki ML, Martin MT, Guyot M. A new-carboline alkaloid isolated from the marine sponge Hyrtios erecta. Tetrahedron Lett. 1996;37:3457-60. (Pubitemid 26164725)
22. Sandler JS, Colin PL, Hooper JNA, Faulkner DJ Cytotoxic β-carboline and cyclic peroxides from the Palauan sponge Plakortis nigra. J Nat Prod. 2002;65:1258-61.
23. Urban S, Hickford S, Blunt J., Munro M. Bioactive marine alkaloids. Curr Org Chem. 2000;4:765-807. (Pubitemid 30611648)
24. Andersen RJ, Faulkner DJ, Cun-heng H, Van Duyne GD, et al Metabolites of the marine prosobranch mollusc Lamellaria sp. J Am Chem Soc. 1985;107:5492-5.
25. Davis RH, Carroll AR, Pierens G.K., Quinn RJ New lamellarin alkaloids from the Australian ascidian, Didemnum chartaceum. J Nat Prod. 1999;62:419-24. (Pubitemid 29165215)
26. Bailly C. A family of anticancer marine pyrrole alkaloids. Curr Med Chem Anti-Cancer Agents 2004;4:363-87.
27. Facompre M, Tardy C, Bal-Mahieu C, Colson P., et al Lamellarin D: a novel inhibitor of topoisomerase I. Cancer Res. 2003;63:7392-99.
28. Vanhuyse M, Kluza J, Tardy C., Otero G, et al Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett. 2005;221:165-75. (Pubitemid 40460403)
29. Quesada AR, Garcia Gravalos MD, Fernandez Puentes JL. Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein. Br J Cancer 1996;74:677-82. (Pubitemid 26300756)
30. Kang H, Fenical W. Ningalins A-D: novel aromatic alkaloids from a Western Australian ascidian of the genus Didemnum. J Org Chem. 1997;62:3254.
31. (a) Lindquist N, Fenical W, Van Duyne GD, Clady J. New alkaloids of the lamellarin class from the marine ascidian Didemnum chartaceum (Sluiter, 1909). J Org Chem. 1988;53:4570.
32. (b) Carrol AR, Bowden BF, Coll JC. Studies of Australian ascidians I. Six new lamellarin-class alkaloids from a colonial ascidian, Didemnum sp. Aust J Chem. 1993;46:489.
33. (c) Urban S, Hobbs L, Hooper JNA, Capon RJ. Lamellarin-S: a new aromatic metabolite from an Australian tunicate, Didemnum sp. Aust J Chem. 1996;49:711.
34. (d) Urban S, Capon RJ. Lamellarins Q and R: new aromatic metabolites from an Australian marine sponge, Dendrilla cactos. Aust J Chem. 1995;48:1491.
35. Boger DL, Soenen DR, Boyce C.W., Hedrick MP, et al Total synthesis of ningalin B utilizing a heterocyclic azadiene Diels-Alder reaction and discovery of a new class of potent multidrug resistant (MDR) reversal agents. J Org Chem. 2000;65:2479-83. (Pubitemid 30235817)
36. Tao HC, Hwang I, Boger DL Multidrug resistance reversal activity of permethyl ningalin B amide derivatives. Bioorg Med Chem Lett. 2004;14:5979-81. (Pubitemid 39531255)
37. Boger DL, Boyce CW, Labroli M.A., Sehon CA, et al Total syntheses of ningalin A, lamellarin O, lukianol A, and permethyl storniamide A utilizing heterocyclic azadiene Diels-Alder reactions. J Am Chem Soc. 1999;121:54-62. (Pubitemid 29047122)
38. Palermo JA, Brasco MFR, Seldes AM Storniamides A-D: alkaloids from a Patagonian sponge Cliona sp. Tetrahedron 1996;52:2727.
39. Yun JM, Sim TB, Hahm H.S., Lee WK, et al Efficient synthesis of enantio-merically pure 2-acylaziridines: facile syntheses of N-Boc-safingol, N-Boc-D-erythrosphinganine, and N-Boc-spisulosine from a common intermediate. J Org Chem. 2003;68:7675-80. (Pubitemid 37186117)
40. Cuadros R, Montejo de Garcini E, Wandosel F, Faircloth G, et al. The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett. 2000;152:23-9. (Pubitemid 30169014)
41. Newman DJ, Cragg GM Marine natural products and related compounds in clinical and advanced preclinical trial. J Nat Prod. 2004;67:1216-38. (Pubitemid 39145623)
42. Crul M, Mathot RA, Giaccone G, et al. Population pharmacokinetics of the novel anticancer agent KRN7000. Cancer Chemother Pharmacol. 2002;49:287-93. (Pubitemid 34253266)
43. Giaccone G, Punt CJA, et al A phase I study of the natural killer T-cell ligand: α-galactosylceramide (KRN7000) in patients with sold tumors. Clin Canc Res. 2002;8:3702-9. (Pubitemid 35424759)
44. Chang DH, Osman K, ConnoUy J., et al Sustained expansion of NKT cells and antigen-specific T cells after injection of galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201:1503-17. (Pubitemid 40664093)
45. Remiszewski SW. The discovery of NVP-LAQ824: from concept to clinic. Curt Med Chem. 2003;10:2393-402. (Pubitemid 37236395)
46. Grant S. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia. Leukemia 2004;18(12):1931-3. (Pubitemid 40028417)
47. Atadja P, Gao L, Kwon P., Trogani N, et al Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004;64:689-95. (Pubitemid 38120911)
48. Catley L, Weisberg E, Tai Y.T., Atadja P., et al NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-22. (Pubitemid 37193603)
49. Seotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs 2002;13:S3-S6.
50. Takahashi N, Li WW, Banerjee D, et al Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001;7:3251-7. (Pubitemid 32963850)
51. Brain EG. Safety and efficacy of ET-743: the French experience. Anticancer Drugs 2002;13:Sll-S14.
52. Lau L, Supko JG, Blaney S, et al Ecteinascidin-743(yondelis) in children with refractory solid tumors. A children soncology group study. Clin Cancer Res. 2005;11:672-7. (Pubitemid 40116894)
53. Proksch P, Edrada RA, Ebel R. Drugs from the seas: current status and microbiological implications. Appl Microb Biotech. 2002;59(2):l25-34.
54. Laverdiere C, Anders KE, Supko J.G., et al Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98(4):832-40. (Pubitemid 36959281)
55. Dubowchik GM, Firesone RA The synthesis of branched steroidal pro-drugs of nitrogen mustard for antitumor targeting via reconstituted LDL. Tetrahedron Lett. 1994;35:4523-6. (Pubitemid 24203115)
56. Delbarre A, Oberlin R, Roques B. Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer. J Med Chem. 1985;28:752-61. (Pubitemid 15026116)
57. Thmas GL, Guo C, Boyd M.R., Fuchs PL Outer-ring stereochemical modulation of cytotoxicity in cephalostatin. Org Lett. 2000;2(1):33-6.
58. Faulkner DJ. Marine natural products. Nat Prod Rep. 2001;18:1-49. (Pubitemid 32160982)
59. D'Auria M.V., Minale L, Riccio R. Polyoxygenated steroids of marine origin. Chem Rev. 1993;93:1839-95.
60. Funel C, Berrue F, Roussakis C., Rodriguez R, et al New cytotoxic steroids from the Indian Ocean sponge Axinella cf. bidderi. J Nat Prod. 2004; 67 (3):491-4. (Pubitemid 38405726)
61. Aoki S, Yoshioka Y, Miyamoto Y., Higuchi K, et al Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp. Tetrahedron Lett. 1998;39:6303-6. (Pubitemid 28374794)
62. Nobutoshi M, Masanori S, Mari M., Motomasa K. Total synthesis of agosterol A: an MDR-modulator from a marine sponge. Chemistry-A Eur J. 2001; 7 (12):2663-70.
63. Cole SPC, Bhardwaj G, Gerlach J.H., Mackie JE, et al Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4. (Pubitemid 23012438)
64. Aoki S, Setiawan A, Yoshioka Y., Higuchi K, et al Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. Tetrahedron 1999;55:13965-72.
65. Wang W, Li F, Alam N., Liu Y, et al New saponins from the starfish Certonardoa semiregularis. J Nat Prod. 2002;65:1649-56. (Pubitemid 35386796)
66. Wang W, Li F, Hong J., Lee CO, et al Four new saponins from the starfish Certonardoa semiregularis. Chem Pharm Bull. 2003;51:435-9. (Pubitemid 41694823)
67. Wang W, Li F, Hong J., Lee CO, et al Bioactive sterols from the starfish Certonardoa semiregularis. J Nat Prod. 2003;66:384-91. (Pubitemid 36384016)
68. Wang W, Hong J, Lee C.O., Im KS, et al Cytotoxic sterols and saponins from the starfish Certonardoa semiregularis. J Nat Prod. 2004;67:584-91. (Pubitemid 38533929)
69. Gan Y, Wientjes MG, Au JL-S. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006;23(6):1324-31. (Pubitemid 43946154)
70. Mukhopadhyay S, Maitra U. Chemistry and biology of bile acids. Curr Sci. 2004;87(12):1666-83. (Pubitemid 41024553)
71. Matile J, Beroua N, Nakanishi K., Wood R. Structural studies by exciton coupled circular dichroism over a large distance: porphyrin derivatives of steroids, dimeric steroids, and brevetoxin B. J Am Chem Soc. 1996;118:5198-206. (Pubitemid 26201540)
72. Guthre JP, Cossa J, Darson BA A water soluble dimeric steroid with catalytic properties, rate enhancements from hydrophobic binding. Can J Chem. 1986;64:2456-69.
73. Schmidt A, Beckert A, Weiss RD Simple procedure for reductive coupling of steroids with a cross-conjugated dienone system. Tetrahedron Lett. 1992;33:4299-300.
74. Pettit GR, Inoue M, Kamano Y, Herald DL, et al. Isolation and structure of the powerful cell growth inhibitor cephalostatin. J Am Chem Soc. 1988; 110 (6):2006-7. (Pubitemid 18090678)
75. Pettit JM, Xu JP, Schmidt JM Isolation and structure of the exceptional Pterobranchia human cancer inhibitors cephalostatins 16 and 1. Bioorg Med Chem Lett. 1995;5:2027-30.
76. Camen B, Raimunda F, Perez-Martin I, Tierry P., et al A convenient synthesis of C-22 and sterioisomers of cephalostatin north 1 side chain from spirostan sapogenin. Org Lett. 2002;4(8):1295-8.
77. Yuexian L, Dias JR Dimeric and oligomeric steroids. Chem Rev. 1997;97:283-304. (Pubitemid 127662447)
78. Shawakfeh KQ, Al-Said NH, Al-Zoubi RM. Synthesis of bis-diosgenin pyrazine dimers: new cephalostatin analogs. Steroids 2008;73(6):579-84.
79. Schmitz FJ, Bowden FJ, Toth SI Marine biotechnology. Antitumor and cytotoxic compounds from marine organisms. Mar Biotechnol. 1993;1:197-308.
80. Rinehart KL, Gloer JB, Cook J.C., Mizsak SA, et al Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc. 1981;103:1857-9. (Pubitemid 11075621)
81. (a) Wright AE, Forleo DA, Gunawardana GP, Gunasekera SP, et al. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J Org Chem. 1990;55:4508-12. (Pubitemid 20274261)
82. (b) Rinehart KL, Holt TG, Fregeau NL, Stroh JG, et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ectei-nascidia turbinata. J Org Chem. 1990;55:4512-15. (Pubitemid 20274262)
83. Fukuzawa S, Matsunaga S, Fusetani N. A highly cytotoxic dimeric steroi-dal alkaloid, from the tunicate Ritterella tokioka. J Org Chem. 1994; 59 (21):6164-6. (Pubitemid 24351134)
84. Ganesan A. The dimeric steroid-pyrazine marine alkaloids: challenges for isolation, synthesis, and biological studies. Angew Chem Int Ed Engl. 1996;35(6):611-15. (Pubitemid 126665365)
85. Moore KS, Wehrli S, Roder H., et al Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci. 1993;90:1354-8. (Pubitemid 23058170)
86. Sills AKJ, Williams JI, Tyler B.M., Epstein DS, et al Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vas-culature. Cancer Res. 1998;58:2784-92. (Pubitemid 28311909)
87. Pettit GR, Day JF, Hartwell J.L., Wood HB Antineoplastic components of marine animals. Nature 1970;227:962-3.
88. (a) Schwartsmann G, Brondani da Rocha A, Mattei J, Lopes RM. Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 2003;12:1367-83. (b) (Pubitemid 36957792)
89. Luesch H, Harrigan GG, Goetz G, Horgen FD. The cyanobacterial origin of potent anticancer agents originally isolated from sea hares. Curr Med Chem. 2002;9:1791-806.
90. (c) Sennett SH, McCarthy PJ, Wright AE, Pomponi SA. Natural products from marine invertebrates: the harbor branch oceanographic institution experience. Pharm News 2002;9:483-8. (Pubitemid 37107980)
91. (d) Mayer AMS. Current marine pharmacology contributions to new drug development in the biopharmaceutical industry. Pharm News 2002;9:479-82.
92. (e) Mayer AMS, Gustafson KR. Marine pharmacology in 2000: antitumor and cytotoxic compounds. Int J Cancer 2003;105:291-9. (Pubitemid 36570039)
93. Pettit GR. Synthetic peptides. Amsterdam: Elsevier; 1982. Vol. 6.
94. Pettit GR, Tan R, Herald D.L., Cerny RL, et al Antineoplastic agents 277, isolation and structure of phakellistatin 3 and isophakellistatin 3 from a Republic of Comoros marine sponge. J Org Chem. 1994;59:1593.
95. Pettit GR, Xu JP, Cichacz Z, Schmidt J.M., et al Antineoplastic agents 303, isolation and structure of the human cell growth inhibitory phakellistatin 4 from the western Pacific sponge Phakellia costata. Heterocycles 1994;40:501.
96. Rinehart KL, Gloer JB, Cook J.C., Mizsak SA, et al Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc. 1981;103:1857-9. (Pubitemid 11075621)
97. Rinehart KL, Gloer JB, Hughes R.G., Renis HE, et al Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 1981;212:933-5. (Pubitemid 11120478)
98. Rinehart KL. Antitumor compounds from tunicates. Med Res Rev. 2000;20:1-27. (Pubitemid 30027559)
99. Vera MD, Joullie MM Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev. 2002;22:102-45. (Pubitemid 34160582)
100. Caufield CE, Musser JH Macrocyclic immunomodulators. Annu Rep Med Chem. 1989;25:195-204.
101. Rinehart KL, Lithgow-Bertelloni AM, Dehydrodidemnin B. WO 9104985; 1991.
102. Raymond E, Paz-Ares L, Izquierdo M., Belanger K, et al Phase I trials with aplidine, a new marine derived anticancer compound. Eur J Can. 2001;37 Suppl 6:S32.
103. Raymond E, Ady-Vago N, Ribrag V., Faivre S, et al Phase I and pharmacokinetic study of aplidine, a marine derived compound, given as a 24 h infusion every 2 weeks in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma (NHL). Ann Oncol. 2000;11 Suppl 4:134.
104. Izquierdo MA, Bowman A, Martínez M, Cicchella B., et al A phase I study of aplidine (APL), a marine derived compound, given as an infusion weekly x 3 in advanced solid tumors and non-Hodgkin lymphoma patients (pts). Ann Oncol. 2000;11 Suppl 4:134.
105. Maroun J, Belanger K, Seymour L., Soulieres D, et al Phase I study of aplidine (APL) in a 1 hour daily infusion x 5 q 3 weeks in patients (pts) with solid tumors and low intermediate grade non Hodgkins lymphomas: a National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) study. Ann Oncol. 2000;11 Suppl 4:134.
106. Williams PG, Yoshida WY, Moore R.E., Paul VJ Tasipeptins A and B: new cytotoxic depsipeptides from the marine cyanobacterium Symploca sp. J Nat Prod. 2003;66:620-4. (Pubitemid 36617883)
107. Gerwick WH, Tan LT, Sitachitta N, Cordell GA Nitrogen-containing metabolites from marine cyanobacteria. In: Cordell GA, editor. The Alkaloids. San Diego: Academic Press; 2001. Vol. 57, pp. 75-184. (Pubitemid 33805341)
108. Schmidt EW, Raventos SC, Bifano M, Menendez A.T., et al Scleritodermin A, a cytotoxic cyclic peptide from the lithistid sponge Scleritoderma nodosum. J Nat Prod. 2004;67:475.
109. Maryanoff BE, Greco MN, Zhang H.C., Andrade-Gordon P, et al Macro-cyclic peptide inhibitors of serine proteases, convergent total synthesis of cyclotheonamides A and B via a late-stage primary amine intermediate. Study of thrombin inhibition under diverse conditions. J Am Chem Soc. 1995;117:1225.
110. Lewis SD, Ng AS, Baldwin J.J., Fusetani N., et al Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A. Thromb Res. 1993;70:173.
111. Schreiber SL, Crabtree GR The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136.
112. Long BH, Wang L, Lorico A, Wang RR, et al. Mechanisms ofresistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991;51:5275-84.
113. Talpir R, Benayahu Y, Kashman Y., Pannell L, et al Hemiasterlin and geodiamolide TA; two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett. 1994;35:4453-6. (Pubitemid 24195061)
114. Coleman JE, de Silva ED, Kong FM, Andersen RJ, et al Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 1995; 51 (39):10653-62.
115. Anderson HJ, Coleman JE, Andersen R.J., Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A, and hemiasterlin B include mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol. 1997; 39 (3):223-6. (Pubitemid 26414259)
116. Gamble WR, Durso NA, Fuller R.W., Westergaard CK, et al Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem. 1999;7:1611-15. (Pubitemid 29347127)
117. Loganzo F, Discafani CM, Annable T, Beyer C, et al. A synthetic analogue of the tripeptide hemiasterlin is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003;63:1838-45. (Pubitemid 36460846)
118. Williams PG, Yoshida WY, Quon M.K., Moore RE, et al The structure of palau'amide, a potent cytotoxin from a species of the marine cyanobacter-ium Lyngbya. J Nat Prod. 2003;66:1545.
119. Li WL, Yi YH, Wu H.M., Xu QZ, et al Isolation and structure of the cytotoxic cycloheptapeptide phakellistatin 13. J Nat Prod. 2003;66:146-8.
120. Pettit GR, Tan R. Isolation and structure of phakellistatin 14 from the western Pacific marine sponge Phakellia sp. J Nat Prod. 2005;68:60-3. (Pubitemid 40175930)
121. Pettit GR, Tan R, Ichihara Y., Williams MD, et al Isolation and structure of the human cancer cell growth inhibitory cyclic octapeptides phakellis-tatin 10 and 11 from Phakellia sp. J Nat Prod. 1995;58(6):961-5.
122. Pettit GR, Clewlow PJ, Dufresne C, Doubek D.L., et al Antineoplastic agents. 193. Isolation and structure of the cyclic peptide hymenistatin 1. Can J Chem. 1990;68:708-11. (Pubitemid 20238110)
123. Pettit GR, Srirangam JK, Herald D.L., Erickson KL, et al Antineoplastic agents. 251. Isolation and structure of stylostatin 1 from the Papua New Guinea marine sponge Stylotella aurantium. J Org Chem. 1992;57:7217-20. (Pubitemid 23035945)
124. Pettit GR, Herald CL, Boyd M.R., Leet JE, et al Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the Western Pacific marine sponge Axinella sp. J Med Chem. 1991;34:3339-40.
125. Kobayashi J, Tsuda M, Nakamura T.I., Mikami Y., et al Hymenamides A and B, new proline-rich cyclic heptapeptides from the Okinawan marine sponge Hymeniacidon sp. Tetrahedron 1993;49:2391-402.
126. Tsuda M, Shigemori H, Mikami Y., Kobayashi J. Hymenamides CE. New cyclic heptapeptides with two proline residues from the Okinawan marine sponge Hymeniacidon sp. Tetrahedron 1993;49:6785-96.
127. Tsuda M, Sasaki T, Kobayashi J. Hymenamides G, H, J, and K, four new cyclic octapeptides from the Okinawan marine sponge Hymeniacidon sp. Tetrahedron 1994;49:4667-80. (Pubitemid 24152189)
128. Kobayashi J, Nakamura T, Tsuda M. Hymenamide F, new cyclic hepta-peptide from marine sponge Hymeniacidon sp. Tetrahedron 1996;52:6355-60. (Pubitemid 26127806)
129. Morita H, Kobata H, Takeya K., Itokawa H. Cyclic peptides from higher plants. V. Pseudostellarin G, a new tyrosinase inhibitory cyclic octapeptide from Pseudostellaria heterophylla. Tetrahedron Lett. 1994;35:3563-4. (Pubitemid 24176483)
130. Morita H, Kayashita T, Kobata H., Gonda A, et al Cyclic peptides from higher plants. VI. Pseudostellarins A-C, new tyrosinase inhibitory cyclic peptides from Pseudostellaria heterophylla. Tetrahedron 1994;50:6797-804. (Pubitemid 24293175)
131. Morita H, Gonda A, Takeya K., Itokawa H. Cyclic peptides from higher plants. 29. Cycloleonuripeptides from Leonurus heterophyllus. Bioorg Med Chem Lett. 1996;6:767-70.
132. Morita H, Kayashita T, Shishido A., Takeya K, et al Cyclic peptides from higher plants. 26. Dichotomins A-E, new cyclic peptides from Stellaria dichotoma L. var. lanceolata Bge. Tetrahedron 1996;52:1165-76.
133. Hiroshi M, Young SY, Takeya K, Itokawa H., et al A cyclic heptapeptide from Vaccaria segetalis. Phytochemistry 1996;42:439-41. (Pubitemid 126655046)
134. Morita H, Takeya K, Itokawa H. Cyclic octapeptides from Stellaria dichotoma var. lanceolata. Phytochemistry 1997;45:811-45.
135. Zhao YR, Zhou J, Wang X.K., Wu HM, et al Three cyclopeptides from Stellaria delavayi. Phytochemistry 1997;46:709-14. (Pubitemid 27483833)
136. Napolitano A, Bruno I, Riccio R., Gomez-Paloma L. Synthesis, structure, and biological aspects of cyclopeptides related to marine phakellistatins 7-9. Tetrahedron 2005;61:6808-15. (Pubitemid 40823019)
137. Garo E, Starks CM, Jensen P.R., Fenical W., et al Trichodermamides A and B, cytotoxic modified dipeptides from the marine-derived fungus Tricho-derma virens. J Nat Prod. 2003;66:423-6. (Pubitemid 36384025)
138. Lin Y, Shao Z, Jiang G., Zhou S, et al Penicillazine, a unique quinolone derivative with 4H-5,6-dihydro-1,2-oxazine ring system from the marine fungus Penicillium sp. (Strain 386) from the South China Sea. Tetrahedron 2000;56:9607-9.
139. Wan XB, Doridot G, Joullie MM Progress towards the total synthesis of trichodermamides A and B: construction of the oxazine ring moiety. Org Lett. 2007;9(6):977-86.
140. Milanowski DJ, Gustafson KR, Rashid M.A., Pannell LK, et al Gymnan-giamide, a cytotoxic pentapeptide from the marine hydroid Gymnangium regae. J Org Chem. 2004;69:3036-42. (Pubitemid 38542556)
141. Leclercq PA, Smith LC, Desiderio DM Jr. Modification, permethylation, and mass spectrometry of arginine-containing oligopeptides at the 100 nanomolar level. Biochem Biophys Res Commun. 1971;45:937-44.
142. Takita T, Shimada N, Yagisawa N., Kato K, et al Chemistry of phegano-mycins, new peptide antibiotics. Proc 15th Symp Pept Chem. 1977:121-6.
143. Hashimoto K, Tsujimura T, Moriyama Y., Yamatodani A, et al Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol. 1996;148:189-200. (Pubitemid 26022450)